Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -47.09% | 27.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -47.09% | 27.27% | |||
| Cost of Revenue | 4.04% | 23.87% | |||
| Gross Profit | -5.68% | -23.77% | |||
| SG&A Expenses | 18.57% | 21.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.36% | 23.38% | |||
| Operating Income | -8.70% | -23.29% | |||
| Income Before Tax | -13.22% | -27.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.22% | -27.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.22% | -27.19% | |||
| EBIT | -8.70% | -23.29% | |||
| EBITDA | -8.72% | -23.43% | |||
| EPS Basic | -12.58% | -22.11% | |||
| Normalized Basic EPS | -12.57% | -22.12% | |||
| EPS Diluted | -13.09% | -22.11% | |||
| Normalized Diluted EPS | -12.57% | -22.12% | |||
| Average Basic Shares Outstanding | 0.57% | 4.15% | |||
| Average Diluted Shares Outstanding | 0.57% | 4.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||